Proteolytic assay-based screening identifies a potent inhibitor of anthrax lethal factor

Microbial Pathogenesis
Hae-Chul ParkMoon-Young Yoon

Abstract

Anthrax lethal factor (LF), a Zn(2+)-dependent metalloprotease, is a key virulence component of anthrax toxin. Here, we used proteolytic assay-based screening to identify novel LF inhibitors from a naturally extracted chemical library. The screening identified four compounds that inhibited in vitro proteolytic activity of LF with an IC(50) of low micromolar range (11-20 μM). Three of these compounds were toxic to the mouse macrophage-like cell line, RAW 264.7. Compound 200 was non-toxic, however, and successfully protected Raw 264.7 cells from a lethal toxin challenge with an IC(50) of 39.2 μM. We also identified possible binding modes of compound 200 by molecular docking.

References

Nov 9, 2001·Nature·A D PanniferR C Liddington
May 9, 2002·Proceedings of the National Academy of Sciences of the United States of America·Richard T CummingsEdward M Scolnick
Jul 26, 2003·Protein Expression and Purification·Joungmok KimMoon-Young Yoon
Jan 14, 2004·Nature Structural & Molecular Biology·Benjamin E TurkLewis C Cantley
Jan 14, 2004·Nature Structural & Molecular Biology·Rekha G PanchalSina Bavari
May 18, 2004·Nature Biotechnology·Dal-Hee MinMilan Mrksich
Jun 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Martino ForinoMaurizio Pellecchia
Mar 6, 2007·Annual Review of Biochemistry·John A T Young, R John Collier

❮ Previous
Next ❯

Citations

Feb 19, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·W E KamanF J Bikker
Dec 18, 2013·Small·Oscar J SantiestebanJ Manuel Perez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Related Papers

Biochemical and Biophysical Research Communications
Joungmok KimMoon-Young Yoon
Biochemical and Biophysical Research Communications
Joungmok KimMoon-Young Yoon
© 2021 Meta ULC. All rights reserved